Idropranolol is a beta–adrenoceptor blocking agent that has never been marketed.

Ibuverine was studied as an antispasmodic agent. Information about the current use of this drug is not available.

Candocuronium is bisquaternary aza steroid derivative with neuromuscular blocking, ganglion blocking, and vagolytic activities. Its potential adjunctive use in anesthesia to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation was briefly evaluated in clinical studies in India, but further development discontinued because of attendant cardiovascular effects, primarily tachycardia that was no worse than but also not an improvement over the clinically established pancuronium bromide.

Nifurizone, a 5-nitrofuran derivative, is an antibacterial agent. It was used for controlling Salmonella choleraesuis in swine. The mode of action of 5-nitrofuran analogues is based on red-ox biotransformation.

Orconazole, an imidazole derivative, was developed by Janssen Pharmaceutical as an antifungal agent, however, this drug has never been marketed

TT-232 is a structural derivative of the natural signal inhibitory peptide somatostatin, with selective antiproliferative and anti-inflammatory properties. TT-232 has no growth hormone release inhibitory effect and does not inhibit the secretion of gastric acid. This analog induces apoptosis in and exerts pronounced antiproliferative effects on various human tumors (colon, pancreas, lymphoma, leukemia, melanoma, hepatoma) cell lines. The growth of human xenografts (prostate, breast carcinoma, lymphoma, melanoma) and animal tumors (colon-26, P-388, S-180, B16, MXT) was inhibited by TT-232 (dose range: 30-750 microg/kg/day) in 54-98% of cases. TT-232 activates SSTR receptors (primarily the SSTR-1), which leads to irreversible cell cycle arrest, followed by secondary induction of apoptosis. TT-232 activates cell cycle inhibitors via SSTR receptors, inhibits tyrosine kinases through interfering with the proliferative signaling cascades, and interacts with an intracellular receptor and an enzyme involved in glycolysis causing translocation of this enzyme to the nucleus, thus inducing apoptosis. TT-232 was a promising candidate in the therapy of human malignancies. TT-232 has passed phase I clinical trials without toxicity and significant side-effects. However TT-232 development has been discontinued.

ATSM CU-64 is an agent for imaging hypoxia in tissues. The agent was developed to be used in PET diagnostic imaging of cancer and showed positive results in phase II of clinical trials in patients with cervical cancer.

Xilobam, a pyrrolidinylidene urea analog was developed as a muscle relaxant. Experiments on animal have shown that this compound was not sedating or anxiolytic in man. Information about the current use of xilobam is not available.